United Therapeutics Corporation (NASDAQ:UTHR) saw two of its insiders unload stock last week. The company’s Chief Executive Officer, Martine Rothblatt, initiated the sale streak by unloading 9,428 shares of Common Stock, directly, on Thursday. The stock was sold in three small transactions, for prices ranging between $93.06 and $93.76 per share, and the insider also exercised his use of stock options. The second insider sale at United was executed by Roger Jeffs, President and Chief Operating Officer at the $4.4 billion market cap biotechnology firm. Jeffs disposed of 10,000 shares of Common Stock, directly, for a price of $91.60 per share, as well as exercising his use of stock options, like his fellow employee.
On another note, this quarter of fiscal 2014 showed positive improvements amongst hedge funds, with most shareholders augmenting the firm’s portfolio participation. Mitchell Blutt’s Consonance Capital Management, for one, increased portfolio activity by 16%, bringing the total company holdings up to 669,690, with an estimated value of $62.9 million and accounting for 9.36% of the hedge funds portfolio holdings.